Reports

Ideas That Generate Results

List of Figures:

Figure 3-1: Global - Leading Causes of Non-Communicable Deaths (%), 2008
Figure 3-2: Global - Number of Cancer Deaths (Million), 2008 & 2030
Figure 3-3: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 3-4: Global - New Cancer Cases by Region (%), 2009
Figure 3-5: Global - Forecast for the New Cancer Cases by Region (%), 2020
Figure 4-1: Global - Pharmaceuticals Market by Therapy Areas (%), 2012 & 2017
Figure 4-2: Global - Cancer Drugs Market (Billion US$), 2012-2017
Figure 4-3: Global - Cancer Drugs Market by Player (%), 2012
Figure 4-4: Global - Cancer Drugs Market by Therapeutic Segment (%), 2012
Figure 5-1: Types of Monoclonal Antibodies
Figure 5-2: Hybridoma Technology for Mouse-derived Monoclonal Antibodies
Figure 7-1: Global - Cancer mAbs Market (Billion US$), 2012-2017
Figure 7-2: Global - Cancer mAbs Market by Product (%), 2012
Figure 7-3: Global - Avastin Sales (Billion US$), 2012-2017
Figure 7-4: Global - MabThera/Rituxan Sales (Billion US$), 2012-2017
Figure 7-5: Global - Herceptin Sales (Billion US$), 2012-2017
Figure 7-6: Global - Erbitux Sales (Billion US$), 2012-2017
Figure 7-7: Global - Vectibix Sales (Million US$), 2012-2017
Figure 7-8: Global - Cancer mAbs Market by Country/Region (%), 2012
Figure 7-9: US - Cancer mAbs Market (Billion US$), 2012-2017
Figure 7-10: Japan - Cancer mAbs Market (Billion US$), 2012-2017
Figure 7-11: Europe - Cancer mAbs Market (Billion US$), 2012-2017
Figure 7-12: Global - Cancer mAbs Market by Player (%), 2012
Figure 8-1: Global - Breakup of Cancer mAbs in Pipeline by Phase

List of Tables:

Table 3-1: Global - Number of New Cancer Cases by Type and Geography (2009)
Table 3-2: Global - Forecast for the Number of New Cancer Cases by Type and Geography (2020)
Table 7-1: Global - List of FDA Approved Cancer mAbs with Year of Approval and Indication
Table 7-2: US - Forecast for the Number of Cancer Cases and Deaths by Types (2013)
Table 7-3: US - List of Approved Cancer mAbs with Year of Approval
Table 7-4: US - Cancer mAbs Expenditure in Clinics (Million US$), 2011 & 2012
Table 7-5: Japan - Number of Cancer Deaths by Type and Gender (2010 & 2011)
Table 7-6: Japan - List of Approved Cancer mAbs with Year of Approval
Table 7-7: EU - Number of Cancer Cases and Deaths by Type (2012)
Table 7-8: EU - List of Approved Cancer mAbs with Year of Approval
Table 8-1: Global - Pipeline Analysis of Cancer mAbs
Table 8-2: Global - Number of Cancer mAbs in Pipeline by Type of Cancer
Table 9-1: Roche - Key Cancer Monoclonal Antibodies in Market
Table 9-2: Roche - Key Monoclonal Antibodies in Pipeline
Table 9-3: Eli Lilly - Key Cancer Monoclonal Antibodies in Market
Table 9-4: Eli Lilly - Key Cancer Monoclonal Antibodies in Pipeline
Table 9-5: GlaxoSmithKline - Key Cancer Monoclonal Antibodies in Market
Table 9-6: GlaxoSmithKline - Key Cancer Monoclonal Antibodies in Pipeline
Table 9-7: Amgen - Key Cancer Monoclonal Antibodies in Market
Table 9-8: Amgen - Key Cancer Monoclonal Antibodies in Pipeline
Table 9-9: Bristol-Myers Squibb - Key Cancer Monoclonal Antibodies in Market
Table 9-10: Bristol-Myers Squibb - Key Cancer Monoclonal Antibodies in Pipeline
Table 9-11: Seattle Genetics - Key Cancer Monoclonal Antibodies in Market
Table 9-12: Seattle Genetics - Key Cancer Monoclonal Antibodies in Pipeline
Table 9-13: Spectrum Pharmaceuticals - Key Cancer Monoclonal Antibodies in Market
Table 9-14: Genmab - Key Cancer Monoclonal Antibodies in Market
Table 9-15: Genmab - Key Cancer Monoclonal Antibodies in Pipeline